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ABSTRACT 
Introduction: Simultaneous pancreas-kidney transplantation (SPKT) outcomes are conditioned in the 
short-term mostly by post-operative complications. In the long-term, cardiovascular (CV) disease and immu-
nological loss are the main limitations to transplant survival. Aims: To analyse retrospectively the results 
from 150 SPKT performed at our centre. Patients and Methods: The 81 females and 69 males had a mean 
age of 35±6 years; they were diabetic for 24±6 years and had been on dialysis for 30±21months (except 5 
preemptive). Anti-lymphocyte globulin, tacrolimus, mycophenolate and steroids were used as immunosup-
pressive therapy. Deceased-donor mean age was 28±11 years. In 28.7% the transplant was performed with 
6 HLA-mismatches. Results: Acute rejection’s incidence was 16%. Ten SPKT patients died; infection was the 
leading cause of death (five cases), followed by Cardiovascular/cerebrovascular disease (three cases). In 21 
patients the pancreas failed, mainly due to thrombosis or bleeding (11 cases), and infection (five cases); in 
two it was due to late acute rejection. In four patients only the kidney failed, due to chronic rejection. Five 
patients lost both grafts, from late acute rejection in four and thrombosis in one. We analyzed the 110 SPKT 
patients (73.3%) with both grafts functioning. Their mean serum creatinine was 1.2±0.4mg/dl; creatinine-
clearance was 76±24 ml/min; fasting glycaemia was 81±10mg/dl; and HbA1c was 5.3±0.4%. Hypertension 
has been treated in 47.2% of patients, in the majority (28.2%) with only one drug. Hyperlipidaemia was 
observed in 19.1% and excessive weight (>25kg/m2) in 17.3%. Conclusions: From our cohort of SPKT, 93.3% 
of patients are alive, 73.3% have both grafts functioning. Rejection was the main cause of late pancreas 
loss. Early mortality was due to infection (3.3%). CV/cerebrovascular disease was the main cause of late 
mortality (2%). The prevalence of hyperlipidaemia and overweight was inferior to 20%. Hypertension was 
the most frequently found CV risk factor.
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INTRODUCTION 
Simultaneous pancreas-kidney transplantation 
(SPKT) is the best treatment for type 1 diabetic 
patients with end-stage renal disease who have the 
conditions for this kind of transplant. The results 
of SPKT are better than those obtained from other 
modalities of pancreas transplantation, such as pan-
creas after kidney (PAK), or pancreas transplantation 
alone (PTA)1. A successful SPKT frees the patient 
from insulin and dialysis-dependence and avoids 
the life-threatening hypoglycaemic episodes. This 
may represent a significant improvement on their 
impaired quality of life. It is unquestionable that 
SPKT leads to a significant improvement in patient 
survival, when compared to those staying under 
dialysis and insulin, or even compared to those who 
underwent a cadaveric kidney alone transplant2. 
Moreover, the pancreas transplant may stop the 
progression or even ameliorate the various second-
ary diabetic complications1,2.
Outcomes of SKPT have improved over time, in 
parallel with other organ transplants1,2,3. However, 
patient and graft loss after SPKT, namely in the early 
phase after surgery, is higher than in kidney trans-
plantation alone. Thrombotic and infectious compli-
cations are the leading causes of graft failure or even 
patient death in the short-term1. Cardiovascular or 
cerebrovascular disease2,3 and also infection1,2 are 
the main limitations for long-term SPKT patient sur-
vival. Immunological loss3 and death with a function-
ing graft3 represent the main causes of graft failure 
in the long-term. It is well known for these patients 
the increase in mortality after graft loss: the relative 
risk of death increased more than 17-fold in recipients 
whose kidney failed and more than 3-fold in recipi-
ents whose pancreas failed1.
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RESUMO 
Introdução: A sobrevivência do transplante de rim-pâncreas (TRP) é condicionada na fase precoce 
pelas complicações inerentes ao próprio acto cirúrgico. A sua perda tardia deve-se essencialmente a 
morte por doença cardiovascular (CV), ou imunológica. Objectivos: Analisámos retrospectivamente os 
resultados dos 150 TRP realizados no nosso centro. Doentes e métodos: Os 81 doentes do sexo F e 69 
do sexo M, tinham uma idade média de 35±6 anos; eram diabéticos há 24±6 anos; e estavam em diálise 
há 30±21meses (excepto 5 preemptive). A terapêutica imunossupressora consistiu em globulina anti-
linfocítica, tacrolimus, micofenolato e corticóides. A média de idades do dador (cadáver) foi 28±11 anos. 
Em 28.7% o transplante foi realizado com 6 incompatibilidades HLA. Resultados: A incidência de rejeição 
aguda foi de 16%. Faleceram 10 doentes: a causa mais frequente foi a infecciosa (5 casos), seguida da 
CV/cerebrovascular (3 casos). Em 21 casos houve falência isolada do pâncreas maioritariamente por 
trombose ou hemorragia (11 casos) e por infecção (5 casos), em 2 casos por rejeição aguda tardia. Em 
4 TRP ocorreu falência isolada do rim, por rejeição crónica. Em 5 casos ambos os enxertos faliram: por 
rejeição aguda tardia 4 doentes; trombose 1 doente. Os 110 TRP (73.3%) que mantêm ambos os enxertos 
funcionantes, têm creatinina de 1.2±0.4mg/dl; clearance da creatinina de 76±24 ml/min; glicemia em 
jejum de 81±10mg/dl; e HbA1c de 5.3±0.4%. Apresentam hipertensão 47,2%, a maioria (28,2%) requer-
endo apenas 1 fármaco. Hiperlipidemia verificou-se em 19,1% e excesso de peso (>25kg/m2) em 17,3% 
dos doentes. Conclusões: Deste grupo de TRP estudado, estão vivos 93.3% e 73.3% têm ambos os 
enxertos funcionantes. Rejeição foi a principal causa de perda tardia do pâncreas. A mortalidade precoce 
deveu-se a infecção (3.3%). Doença CV/cerebrovascular foi a causa mais frequente de mortalidade tardia 
(2%). A prevalência de hiperlipidemia e excesso de peso foi inferior a 20%. Hipertensão foi o factor de 
risco CV mais frequentemente encontrado.
Palavras-chave: morte do doente; perda de enxerto; resultados a longo-prazo; transplantação reno-pan-
creática
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Pancreas-Kidney Transplantation: Analysis of 150 patients from one Centre in Portugal
The aim of this study was to analyze the outcome 
of the SPKT performed at our centre and to search 
for possible factors associated with the outcome.
PATIENTS AND METHODS 
From May 2000 to October 2012, 150 type 1 dia-
betic patients underwent SKPT at the Transplantation 
Department of our Hospital. All the procedures were 
performed using grafts form deceased donors, both 
grafts from the same donor, and using systemic-
enteric drainage (venous drainage to the iliac vein; 
exocrine drainage through an enteric anastomosis 
of the pancreatic-duodenal arch). Only patients with 
a minimum follow-up of 3 months were considered 
for this retrospective analysis.
Results are presented as mean ± standard devia-
tion for continuous, normally distributed variables, 
and as percentages for categorical data. Patient sur-
vival was determined from the time of SPKT until 
death or end of follow-up. Death-censored kidney 
graft survival was determined from the time of kidney 
transplantation until kidney retransplantation, return 
to dialysis, or end of follow-up. Death-censored pan-
creas graft survival was determined from the time 
of SPKT until pancreas failure or end of follow-up. 
Survival analysis was performed using the Kaplan-
Meier (product-limit) estimator of survival.
These 150 patients, 81 females and 69 males, had 
a mean age of 35±6 years at transplantation date. 
They were diabetic for 24±6 years; and had been on 
dialysis for 30±21months, excepting five patients who 
received a pre-emptive transplant. Anti-lymphocyte 
globulin, tacrolimus, mycophenolate and steroids were 
used as induction therapy. Deceased-donor mean age 
was 28±11 years. In 28.7% of the patients the trans-
plant was performed with 6 HLA-mismatches.
RESULTS 
The median admission time was 20 days. Global 
acute rejection incidence (for kidney, pancreas or both 
grafts) was 16%. Delayed kidney graft function, defined 
for dialysis need in the first week, occurred in 16%. 
In the vast majority of patients whose pancreas did 
not have complications, insulin administration could 
be stopped during the first hours after transplantation 
(median 0 days).
In 21 patients the pancreas failed, mainly (16 cases) 
in the very early period (<3 months) due to thrombosis 
(eight cases) or bleeding (three cases) and local infection 
leading to graft removal (five cases); late pancreas loss 
was due to late acute rejection (two cases), atheroem-
bolism after coronary angiography using lower limb access 
(one case) and due to unknown cause in two cases.
In four patients only the kidney failed, due to 
chronic rejection, and these were late losses. In five 
others, both grafts failed: in one case it was an early 
loss due to thrombosis of both grafts; and in four 
it was due to late (> 6 months) acute rejection – in 
three cases we have confirmed patient non-compli-
ance to medication. Tacrolimus trough levels were 
undetectable or markedly below the expected for 
this follow-up time (7-9 ng/ml).
Death occurred in 10 patients: in five during the 
early period, and later in five others. Analyzing the 
causes of patient death from the point of view of 
the different periods (< 12months vs. > 12 months): 
early deaths were due to post-operative sepsis (three 
cases), aspergillosis (one case), and unclear cause 
(one case); late deaths were caused by myocardial 
infarction (two cases), stroke (one case), CMV disease 
(one case) and digestive haemorrhage (one case). 
Globally, infection was the leading cause of death 
(five cases), followed by cardiovascular (CV) or cere-
brovascular disease (three cases). Table 1 summarizes 
the causes of graft failure and patient death.
At the last visit, 110 SPKT patients (73.3%) main-
tained both grafts functioning. Their mean serum crea-
tinine is 1.2±0.4mg/dl; creatinine clearance is 76±24 
ml/min; fasting glycaemia is 81±10mg/dl; and 
HbA1c=5.3±0.4%. Hypertension has been treated in 
52 SPKT (47.2%), in the majority (31SPKT – 28.2%) 
with a single drug, mostly a beta-blocking agent. Hyper-
lipidaemia was observed in 23 patients (20.9%) and 
excessive weight (> 25kg/m2) in 19 patients (17.3%).
Survival rates (death-censored) obtained for this 
cohort of SPKT at our centre for patient, kidney and 
pancreas, respectively, were: at 1 year 97%, 97% 
and 85%; at 5 years 94%, 93% and 78%; and at 10 
years 91%, 79% and 69% (Graph 1).
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DISCUSSION 
There are no longer any doubts that SPKT offers 
the best results to treat type 1 diabetic patients with 
end-stage renal disease. The last position statement 
of the American Diabetes Association4 has confirmed, 
again, their previous recommendation5 of pancreas 
transplantation for these patients, preferably done 
simultaneously to a kidney transplant, given the 
better pancreas survival of SPKT4,5. Also from a point 
of view of quality of life, SPKT can provide significant 
benefit6,7. The successive International Pancreas 
Transplant Registry (IPTR) reports have confirmed 
the progressive improvement in SPKT outcome over 
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Table 1
Causes of graft failure and patient death.
(Total =150 SPK) Timing of occurrence Main cause Specific cause
Pancreas loss (n=21) Very early* loss (n=16)
*(follow-up <3 months)
Thrombosis (n=8) Pancreas graft thrombosis (n=8)
Bleeding (n=3) Peri-graft bleeding (n=3)
Infection (n=5) Pancreatic leak/ abdominal infection (n=5)
Late loss (n=5) Acute rejection (n=2) Unsolved acute rejection (n=2)
Atheroembolism (n=1) (after coronariography) 
Unknown (n=2)
Kidney loss (n=4) Late* loss (n=4)
*(>6 months)
Chronic rejection (n=4)
Pancreas and kidney loss (n=5) Early loss (n=1) Thrombosis (n=1) Pancreas and kidney graft thrombosis (n=1)
Late* loss (n=4)
*(>6 months)
Acute rejection (n=4) Non-compliance confirmed (n=3)
Non-compliance unconfirmed (n=1)
Patient death (n=10) Early death (n=5) Infection (n=4) Post-operative sepsis (n=3)
Aspergillosis (n=1)
Unknown (n=1)
Late* death (n=5)
*(follow-up >12 months)
Infection (n=1) CMV disease (n=1)
Cardiovascular / cerebrovascular disease (n=3) Stroke (n=1)
Myocardial infarction (n=2)
Digestive haemorrhage (n=1) 
Graph 1
Patient and graft survival rates of the 150 SPKT (death-censored)
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the past decades1,8,9. However, it seems that a maxi-
mum and a plateau was reached in the survival 
curves, because no further significant improvements 
have been observed in the last 10 years1.
Pancreas graft outcome is determined mostly by 
the success in early post-operative period. Throm-
bosis, bleeding, pancreatic leaks and infection after 
surgery are normally defined as technical failures. In 
the last IPTR1, near 9% of the losses were reported 
as due to technical failure. It is 10.7% in our own 
experience (16/150 patients), not too different from 
the international results recorded on 25000 SPKT1. 
Thrombosis remained the main cause of early pan-
creas graft loss, as reported by large centers2,3.
Pancreas losses due to acute rejection were 
observed in our study group in 6 SPKT (4%), but in 
half of them non-compliance of the patients to immu-
nosuppression was verified. Blindness or very 
impaired vision may be a real problem for these 
patients to strictly follow the medication and this 
was the case in at least one patient. Thus, if we 
exclude the “expected” losses associated with con-
firmed/confessed non-compliance, we obtain a rate 
of 2% of “unexpected” acute rejection loss, similar 
to that observed in large series1,8.
Kidney graft loss occurred in the late period in all 
but one of the 9 patients of our study group with kidney 
failure. Rejection was the main cause of these late losses 
and this has also been observed by others2,3.
Systemic vascular disease, CV and cerebrovascular 
disease are strongly associated with an increased 
risk of patient death2. In our own experience, infec-
tion in the early period (3.3%) and CV/cerebrovascular 
disease (2%) in the late period were the leading 
causes of patient death. These same reasons for 
patient death were reported by the IPTR1; and the 
authors observed that death due to infection peaked 
between 3 and 12 months.
Hypertension was the most frequently found CV 
risk factor, although its prevalence was inferior to 
50% and in only 28.2% requiring more than one 
drug. Beta-blocking agents were the most often pre-
scribed drugs with anti-hypertensive properties, even 
when the goal is not necessarily to treat hyperten-
sion. In fact, in some of these patients high blood 
pressure was not recorded. However, it is our policy 
to maintain this medication, given its cardio-protec-
tive effects, especially if the patients had previously 
been under this drug. The prevalence of hyperlipi-
daemia and excessive weight was inferior to 20% in 
our SPKT patients.
Compared to kidney transplantation alone, SPKT 
is known to have more complications: a higher rate 
of readmissions10 and early surgical complications 
that may lead to relaparotomy in more than 30% of 
cases3,11. Despite these feared complications and 
the initial increased risk (compared with those 
patients in the waiting list for transplant), trans-
planted patients perform better at 1 year12. Moreover, 
and against initial concerns, 10-year results do not 
confirm a higher mortality of diabetics after SPKT 
versus kidney transplantation alone13. The improve-
ment in quality of life and the effect on long-term 
diabetic complications justify the option for surgery12. 
The developed LYFT scores (life years from trans-
plant), which assess life enhancement achieved by 
each transplant, was greater for diabetics with a 
SPKT than with kidney transplantation alone14. Thus, 
it is currently stated that SPKT is the most cost-
effective treatment for patients with type 1 diabetes 
and end-stage renal disease15.
The authors of the latest IPTR reported a 10-year 
patient survival over 70%16. Considering only SPKT 
recipients who reached the 1-year mark with both 
grafts alive, they reported a 10-year survival rate 
around 66 % for the kidney and 62% for the pancreas 
grafts. In a more recent analysis, the 10-year pancreas 
graft function for SPKT was 68%16. We have pub-
lished the 10-year results of SPKT at our centre two 
years ago17 and they were not inferior to the inter-
national results. Those good outcomes and survival 
rates are substantiated by the results obtained in 
this cohort of patients with extended follow-up.
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